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Comparison of Targeted Mass Spectrometry Techniques
with an Immunoassay: A Case Study for HSP90α
Cos¸kun Gu¨zel, Natalia I. Govorukhina, Christoph Stingl, Lennard J. M. Dekker,
Alexander Boichenko, Ate G. J. van der Zee, Rainer P.H. Bischoﬀ, and Theo M. Luider*
Purpose: The objective of this study is to better understand factors governing
the variability and sensitivity in SRM and PRM, compared to immunoassay.
Experimental design: A 2D-LC–MS/MS-based SRM and PRM assay is
developed for quantitative measurements of HSP90α in serum. Forty-three
control sera are compared by SRM, PRM, and ELISA following the
manufacturer’s instructions. Serum samples are trypsin-digested and
fractionated by strong cation exchange chromatography prior to SRM and
PRM measurements. Analytical parameters such as linearity, LOD, LOQ,
repeatability, and reproducibility of the SRM, PRM, and ELISA are determined.
Results: PRM data obtained by high-resolution MS correlate better with
ELISA measurements than SRM data measured on a triple quadrupole mass
spectrometer. While all three methods (SRM, PRM, and ELISA) are able to
quantify HSP90α in serum at the ng mL–1 level, the use of PRM on a
high-resolution mass spectrometer reduces variation and shows comparable
sensitivity to immunoassay.
Conclusions and clinical relevance: Using fractionation, it is possible to
measure ng mL–1 levels of HSP90α in a reproducible, selective, and sensitive
way using PRM in serum. This opens up the possibility to use PRM in a
multiplexed way as an attractive alternative for immunoassays without the
use of antibodies or comparable binders.
1. Introduction
Targeted proteomics by SRM on triple quadrupole mass spec-
trometers is a widely used strategy to quantify multiple proteins
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in complex body ﬂuids like serum.[1–3]
While SRM is a highly selective method,
interferences in complex biological sam-
ples often limit sensitivity in compari-
son to immunoassays unless appropri-
ate sample preparation is performed.[4–6]
Co-eluting peptides with a precursor ion
mass close to the peptide of interest may
result in fragment ions that overlap with
the targeted transitions resulting in con-
siderable chemical noise. Such noise lim-
its sensitivity and contributes to dimin-
ished accuracy and precision.While SRM
has emerged as the most widely used
experimental approach to quantify pro-
teins in biological samples by MS,[7,8] it
is nevertheless challenging to quantify
low levels of proteins in biological sam-
ples like serum or plasma due to the
limited loading capacity of capillary or
nano-LC columns and to the often in-
suﬃcient resolution needed to separate
interfering compounds. This is the rea-
son that ligand binding assays and no-
tably ELISA are routinely used for pro-
tein bioanalysis despite their limitations
such as the high development cost for sensitive, well-
characterized antibodies, and cross-reactivity with other
proteins or interference from other ligands binding to the target
protein.[9] Advantages of the immunoassay technology are the
high sensitivity (detection limits < 1 ng mL–1)[10] and the ease
with which they can be performed in a high-throughput format.
While multiplexing is possible with immunoassays, for example
those based on ﬂow cytometry, analytical quality generally
suﬀers.[11] PRM using high-resolution MS[12] goes beyond
SRM in that it covers a wider dynamic concentration range and
provides data with higher mass accuracy (ppm- to sub-ppm level)
thus reducing interferences caused by co-eluting compounds
with similar but not identical mass transitions.[12,13] Moreover,
PRM methods for individual peptides are easier to set up, since
all transitions are monitored and optimal transitions can be
retrieved and combined in a post-analysis way.[14] Literature on
PRM shows the feasibility of the approach for quantiﬁcation
of proteins in complex biological samples after proteolytic
digestion.[13,15,16] Notably Domon and coworkers published
on the use of PRM in large-scale experiments.[17–21] However,
reaching the ng mL–1 level in body ﬂuids without using aﬃnity
binders (e.g. immunoglobulins) remains a challenge. This study




with a commercially available and frequently used immunoas-
say. SRMandPRMhaveboth thepossibility tomeasure pro-
teins in amultiplexedway in complex sampleswithout theuse
of antibodies andother types of speciﬁc binders. A separation
(e.g. SCX fractionation) that can also beperformedby automa-
tion is necessary to reduce ion suppression and the eﬀect of
interfering compounds. It is concluded that notably PRMthat
makesuseof high resolutionMS reaches sensitivity compa-
rablewith the immunoassay (ngmL–1). For PRMeven abetter
reproducibilitywasobserved compared to the immunoassay.
This opensways to address in amultiplexedmanner complex
samples such as serum for quantitative analysis of dozensof
proteins in a single runusing a relatively small volumeof serum
(7μL asused inpresent study). Thepresent study addresses
amedical need tomeasure sets of proteins forwhichnoanti-
bodies or partly characterized antibodies are available and if the
amount of serumsample is limited, for instance in population
studies.
shows the feasibility to measure low protein levels (ng mL–1)
in pre-fractionated, trypsin-digested serum in a reproducible
manner. As an example, we targeted HSP90α, a protein that is
upregulated in various cancers and is thus pursued as a target
for early diagnosis, prognosis, and anticancer therapy.[22–24] It
plays a crucial role in protein folding and assists in removal of
misfolded proteins. In this study, we compared the concentra-
tion of HSP90α in 43 sera from healthy subjects measured by
SRM, PRM and a commercially available ELISA with respect to
comparability, repeatability, and sensitivity.
2. Experimental Section
2.1. Samples
Forty-three serum samples were obtained from the Department
of Gynecology (UMCG). All newly referred women were rou-
tinely asked to give written informed consent for collection and
storage of pretreatment and follow-up serum samples in a serum
bank for future research. Relevant data and follow-up results were
retrieved and transferred to an anonymous, password-protected
database. Identity was protected by study-speciﬁc, unique codes
and the true identity is only known to two dedicated data man-
agers. According to Dutch regulations, these precautions mean
that no further institutional review board approval is needed
(http://www.federa.org). The serum samples used for this study
were from women referred to the UMCG for an abnormal cy-
tological analysis but who did not show any signs of developing
cervical cancer upon follow-up examination. Glass tubes (Becton
Dickinson, #367953), with a separation gel and micronized sil-
ica to accelerate clotting, were used for blood collection. Serum
was prepared by letting freshly collected blood coagulate at room
temperature at least for 2 h (till 8 h) followed by centrifugation at
room temperature for 10 min at 3000 rpm. Serum samples were
stored at −80 °C in aliquots until analysis.
2.2. Prefractionation by SCX Chromatography
Forty-three serum samples from healthy subjects (Supporting
Information Table S1) were analyzed and a sample of pooled
serum from a separate set of healthy volunteers containing ap-
proximately 100 ng mL–1 HSP90α was used as quality control
(QC1). Sevenmicroliters from each serum sample was diluted 47
times in 0.01%RapiGest SF (Waters, Milford, MA) in 50mM am-
monium bicarbonate pH 7.8, reduced using 15 mM DTT, alky-
lated with 15mM iodoacetamide (IA), and subsequently digested
by adding 30 μL trypsin (100 μg mL–1 3 mM Tris-HCl pH 8.8)
(Gold, MS Grade, Promega, Madison, WI) at 37 °C overnight.
The enzymatic reaction was stopped by adding 50% FA in wa-
ter to reach a ﬁnal concentration of 0.5–1.0% FA. Digested sera
were spiked with 40 fmol of two SIL (stable isotope-labeled) pro-
teotypic peptides YIDQEELNK (13C615N2) and DQVANSAFVER
(13C615N4) (Thermo Fisher Scientiﬁc, Bremen, Germany; purity
of>97% as stated by the manufacturer (Ultimate grade)). Subse-
quently, the digested samples were desalted using amacroporous
reversed phase mRP-C18 column (Agilent, Palo Alto, California,
USA; 4.6 mm× 50 mm) at a ﬂow rate of 750 μL min–1 according
to Boichenko et al.[25] and oﬄine fractionated on a Luna 5 μm,
150 × 2 mm SCX column (Phenomenex, Torrance, CA) under
the following conditions: buﬀer A (14 mM KH2PO4, 24 mM
H3PO4, pH 2.5, adjusted with 37% (w/w) HCl) in 25% (v/v) ace-
tonitrile (HPLC grade; Biosolve, Valkenswaard, the Netherlands)
in Milli-Q water; buﬀer B (buﬀer A containing 350 mM KCl);
linear gradient from 100% buﬀer A to 40% buﬀer B in 40 min,
followed by a wash with 100% buﬀer B until 45 min at a ﬂow
rate of 200 μL min–1 and equilibration of the column in buﬀer A
for 17 min. All chemicals used for SCX fractionation were pur-
chased from Sigma–Aldrich (St Louis, MO). Fifty microliter frac-
tions (180 fractions in total for each serum sample) were col-
lected in 384-well plates (VWR, Amsterdam, the Netherlands)
and sealed with an adhesive aluminum foil (VWR, Amsterdam,
the Netherlands). Fractions were dried down in SpeedVac con-
centrator (RVT4104, Scientiﬁc Savant, San Jose, CA) and sub-
sequently stored at –20 °C until further analysis. Samples were
reconstituted in 0.1% FA prior SRM and PRM measurements.
Figure 1 shows a general ﬂowchart of how the study was
performed.
2.3. SRM
SRM for quantitative measurements of HSP90α in the 43
SCX-fractionated serum digests was performed targeting the
two proteotypic peptides YIDQEELNK and DQVANSAFVER.
The peptides were selected after analyzing a tryptic digest of
recombinant HSP90α (Genway Biotech Inc, San Diego, CA)
by LC–MS/MS, since they generated the most intense frag-
ment ions. The shotgun MS proteomics data have been de-
posited to the ProteomeXchange Consortium via the PRIDE[26]
partner repository with the dataset identiﬁer PXD007601 and
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Figure 1. Flowchart of experimental design.
https://doi.org/10.6019/PXD007601. Peptides containing poten-
tial missed cleavage sites, methionine, cysteine or ragged ends
KK, KR, and RR were excluded. An online BLAST analysis (Pro-
gram: NCBI BLASTP 2.2.29, database: UniProtKB database, Jan-
uary 3, 2014) showed that YIDQEELNK can be used to quantify
HSP90α (P07900) andHSP90β (P08238) while DQVANSAFVER
is speciﬁc for HSP90α only (85.8% sequence homology between
HSP90α and HSP90β). The possibility of detection of HSP90β
is fairly small, since this protein is present at much lower lev-
els in serum levels (1–2 ng mL–1)[27,28] than HSP90α. SCX-
fractionated peptides were separated using a nanoACQUITY LC
system equipped with an RP analytical BEH300 C18, 300 A˚,
1.7 μm, 75 μm × 200 mm column. Samples were desalted at a
ﬂow rate of 8 μL min–1 with a C18 trap column, 5 μm, 100 A˚,
180 μm × 20 mm for 5 min using 0.1% formic acid (FA) in
water prior separation. Separation was performed on the above-
mentioned analytical column at a ﬂow rate of 300 nL min–1 with
0.1% aqueous FA (mobile phase A) and 0.1% FA/ACN (mo-
bile phase B) as solvents with a linear gradient from 1.5% B at
0 min to 40% B at 30 min. The column was washed with 80%
B for 4.9 min and equilibrated with 1.5% B for 24.9 min. All
LC solvents were UHPLC grade and purchased from Biosolve
(Valkenswaard, the Netherlands). The nanoACQUITY LC system
was connected to a Xevo TQ-S (Waters Corp., Milford, MA) triple
quadrupole mass spectrometer in positive ESI mode. SRM sig-
nals were recorded for all samples in a single measurement for
the doubly charged peptide precursor ions YIDQEELNK (m/z
580.29 for the 13C615N2 labeled peptide) and DQVANSAFVER
(m/z 623.31 for the 13C615N4 labeled peptide). The following pa-
rameters were set using a nanoﬂow Z-spray ion source: capillary
voltage 3000 V, nebulizer gas (nitrogen) 0.15 bar, collision gas
ﬂow 0.15 mL min–1 (argon), source temperature 70 °C, LM/HM
(lowmass/highmass) quad 1 resolution 3.0/15.20, LM/HMquad
2 resolution 2.90/14.80, ion energy 0.9, and cycle time was set to
automatic operation. The selected transitions for YIDQEELNK
and DQVANSAFVER are shown in Table 1. The indicated colli-
sion energy varied from 15–18 and 17–19 V depending on the
fragment ion, respectively. The SRM signals were integrated us-
ing Skyline software (version 3.5.0.9321) tool[29] and HSP90α
concentration was calculated by using the peak area ratio of en-
dogenous and SIL peptide.
The two peptides were found in six (on average) SCX frac-
tions. These six fractions were pooled to obtain a QC2 sample.
A serial dilution of ﬁve SIL peptide concentrations (calibrants)
between 0–30 ng mL–1 (i.e. 0, 0.3, 1.2, 3.0, 6.0, and 30.0 ng
mL–1) was prepared in the QC2 sample and in its pure condi-
tion (dissolved in just 0.1% aqueous FA). Three microliters of
each concentration was injected onto the nano-LC–MS. Subse-
quently, regression analysis was performed by plotting the con-
centration versus total peak area (of all related y-transitions) of
each SIL peptide. The proteomics data (.raw and .mzML ﬁles)
and the transition list (.csv ﬁle) were deposited in the Peptide At-
las SRM Experiment Library assigned with identiﬁer PASS01047
(http://www.peptideatlas.org/PASS/PASS01047).
To determine the variability (in CV%) of the transitions (en-
dogenous and SIL) of YIDQEELNK and DQVANSAFVER for all
43 serameasured, the percent contribution of each transitionwas
calculated by the ratio of its peak area to the total peak area from
all transitions for each serum sample. Considering that the inten-
sities of the observed transitions diﬀer considerably, we also cal-
culated weighted CV. The weighted CV (in weighted%) for each
transition was calculated by multiplying the CV% with the aver-
aged peak area ratio transition/total transition of the 43 samples.
Additionally, the statistical signiﬁcance (unpaired t-test) was de-
termined of the weighted CVs between YIDQEELNK and DQ-
VANSAFVER (endogenous and SIL) for both SRM and PRM.
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Table 1. Selected transitions for YIDQEELNK (y5, y6, and y7) and DQVANSAFVER (y7, y8, and y9) with their corresponding fragment masses that were
used to perform quantitative LC–MS/MS assays in the SRM and PRMmode. Both CV and weighted CV (see text for discussion) were calculated from 43
SCX-fractionated serum samples. Signiﬁcantly, more variation (weighted CV) was observed for endogenous DQVANSAFVER than for YIDQEELNK when
measured by SRM. PRM measurements did not show such signiﬁcant diﬀerences. The SIL peptides showed a similar eﬀect, although to a lesser extent
because on average ﬁve times more SIL peptide was applied than the measured endogenous peptide (one outlier by PRM (sample no. 2, see Supporting
Information Figure S3) was observed and this sample was removed from CV analysis only).
Peptide y5 y6 y7
YIDQEELNK (m/z 576.28, +2) 632.33 760.38 875.41
CV%/weighted CV% SRM: 31.8/2.5 SRM: 47.7/2.6 SRM: 3.9/3.4
PRM: 13.3/0.7 PRM: 9.9/0.7 PRM: 1.1/1.0
YIDQEELNK (SIL) (m/z 580.29, +2) 640.34 768.40 883.43
CV%/weighted CV% SRM: 21.4/1.3 SRM: 26.2/1.0 SRM: 2.3/2.1
PRM: 5.4/0.3 PRM: 6.7/0.4 PRM: 0.6/0.5
Peptide y7 y8 y9
DQVANSAFVER (m/z 618.30, +2) 822.41 893.45 992.52
CV%/weighted CV% SRM: 26.9/5.4 SRM: 15.0/8.0 SRM: 22.3/6.0
PRM: 3.8/0.9 PRM: 2.5/1.2 PRM: 2.9/0.8
DQVANSAFVER (SIL) (m/z 623.31, +2) 832.42 903.46 1002.52
CV%/weighted CV% SRM: 10.5/2.2 SRM: 5.8/3.1 SRM: 6.0/1.4
PRM: 1.9/0.4 PRM: 1.2/0.6 PRM: 1.6/0.4
2.4. PRM
The identical 43 SCX-fractionated serum digests and same serial
dilutions as described in the previous section were measured by
PRM based on a single measurement and analyzed in Skyline.
These measurements were carried out on a nano-LC system (Ul-
timate 3000 RSLCnano, Thermo Fisher Scientiﬁc, Germering,
Germany) online coupled to an Orbitrap Fusion mass spectrom-
eter (Thermo Fisher Scientiﬁc, San Jose, CA, US). Samples were
loaded onto a trap column (PepMap C18, 300 μm ID × 5 mm
length, 5 μm particle size, 100 A˚ pore size; Thermo Fisher Sci-
entiﬁc), washed and desalted for 5 min using 0.1% TFA/water
as loading solvent. Next, the trap column was switched in-line
with the analytical column (PepMap C18, 75 μm id × 250 mm,
2 μm particle and 100 A˚ pore size, Thermo Fisher Scientiﬁc).
Peptides were eluted with the following binary gradient starting
with 12% solvent B for 4 min and then from 12 to 25% solvent
B in 14.7 min, where solvent A consisted of 0.1% FA in water,
and solvent B consisted of 80% acetonitrile and 0.08% FA in wa-
ter. The column ﬂow rate was set to 250 nL min–1 and the oven
temperature to 40 °C. All LC solvents were from identical UH-
PLC grade as mentioned above in the previous section. For ESI,
nano ESI emitters (New Objective, Woburn, MA) were used and
a spray voltage of 1.8 kV was applied. For PRM of the doubly
charged precursor ions of YIDQEELNK and DQVANSAVER (en-
dogenous and SIL), we used the targeted MS/MSmode set up as
follows: isolation width of 1.4 Da, HCD fragmentation at a nor-
malized collision energy of 24%, ion injection time of 502 ms
(by setting the AGC target to 500 000 ions), Orbitrap resolution
of 240 000. Selection of precursor ions was time scheduled (0–
5.8 min for YIDQEELNK; 5.8–20 min for DQVANSAFVER) and
each duty cycle consisted of two targeted MS/MS scans (endoge-
nous and SIL form of a peptide) yielding a scan rate of approxi-
mately 0.9 Hz. Fluoranthene (202.0777 Da) was infused as lock
mass (Easy IC option active). The MS proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE[26]
partner repository with the dataset identiﬁer PXD006618 and
https://doi.org/10.6019/PXD006618.
The variabilities (CV and weighted CV) of each fragment ion
were calculated as described above for SRM. To investigate the
eﬀect of MS/MS resolution independently from diﬀerent instru-
mental parameters, we set up a PRMmethod where MS/MS de-
tection was conducted in the linear ion trap (resolution approx-
imately 0.35 Da FWHM) of the Orbitrap Fusion MS. The value
of a high-resolution mass spectrometer (PRM) in contrast to a
triple-quad instrument (SRM) was demonstrated by comparing
the presence of co-eluting peaks and MS2 spectra with identi-
cal samples (four SCX fractions) measured in PRM and by PRM
at quadrupole ion trap resolution (IT-PRM) of the Orbitrap in-
strument under identical conditions. The IT-PRM method was
set up in such a manner that MS/MS spectra were acquired in
the ion trap (normal scan rate, AGC target of 100 000 ions, and
maximum injection time of 500 ms). All other parameters were
identical to the common PRM method described above. To ex-
clude that diﬀerences between SRM and PRM are an eﬀect of
diﬀerent experimental setup (such as type of column, gradient,
and run time) four fractions of three diﬀerent SCX-fractionated
serum digests with relative high co-eluting peaks which were
observed by SRM were also measured by IT-PRM. To gain in-
sight in the eﬀects of co-elution, peak ratios (between peak areas)
were calculated between transitions of the endogenous peptides
YIDQEELNK and DQVANSAFVER at the apex, half-height, and
one-quarter-height on the right side of the mass spectral peak
and corresponding SIL peptides in pure condition (0.1% aque-
ous FA). Theweighted CVswere calculated as described above for
each transition at each peak height and evaluated. It was assumed
that intensities and ratios were similar if interferences were not
present.
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2.5. Data Analysis (LOD/LOQ, Repeatability, Reproducibility, and
Stability)
Linearity, LOD, and LOQ of the HSP90α-derived peptides were
calculated based on the slope (S) and the residual standard devia-
tion of the slope (σ ) from linear regression analysis according to
ICH guidelines (http://www.ich.org) for single measurements.
The LOD was deﬁned as 3.3 × σ /S and the LOQ as 10 × σ /S.
Correlations were plotted to determine the relationship between
both endogenous HSP90 peptides and linear regression coeﬃ-
cients were calculated.
To evaluate the repeatability, three technical replicates (three
SRM or PRM measurements of an SCX-fractionated QC1 sam-
ple) were measured over a short time period (<4 days; kept at
4 °C), and CVs in percentages were calculated. Additionally, for
stability testing the SCX-fractionated QC1 sample was repeatedly
measured over a longer period with long-term intervals (ranging
from 4 days to 6months) and were kept at 4 °C during storage) by
SRM and PRM. CVs of HSP90α concentrations were calculated
for both YIDQEELNK and DQVANSAFVER. To determine the
matrix eﬀect on the two SIL peptides, a regression analysis was
performed of pure (dissolved in 0.1% aqueous FA) and matrix-
spiked (spiked into background of SCX fractions) samples over a
range of 0–30 ng mL–1 (described above in the section: “SRM”)
measured by SRM and PRM. From these calibration curves the
slopes were compared between both matrix-spiked and pure SIL
peptides.We calculated the ratio (expressed in percentages) of the
mean peak areas of calibrants related to matrix-spiked and pure
SIL peptides. Statistical diﬀerences were calculated and a proba-
bility lower than 0.05 was considered to be signiﬁcant.
2.6. ELISA-Based Quantiﬁcation
HSP90α was quantiﬁed in the identical set of 43 sera includ-
ing the QC1 sample with a commercial ELISA (Enzo Life Sci-
ence, ADI-EKS-895). This assay has been described in several
publications.[30–33] Brieﬂy, 100 μL of diluted serum (1:10 in
Sample Diluent buﬀer) was incubated for 1 h at room tem-
perature in the microtiter plate precoated with anti-HSP90α
antibody. Subsequently, a 400× diluted HSP90α monoclonal an-
tibody conjugated to HRP in HRP diluent was added followed
by stabilized tetramethylbenzidine substrate solution. The re-
action was stopped by adding 100 μL of acidic stop solution
provided by the manufacturer. The HSP90α standard (part no.
80–1564, Enzo Life Science, ADI-EKS-895) with seven dilutions
(i.e. 0.0625, 0.125, 0.250, 0.500, 1.000, 2.000, and 4.000 ng mL–1
including a zero standard) was used for calibration. The ab-
sorbance for individual samples and the serial dilutions (two mi-
crotiter plates in total) were measured on a Multiscan Ascent
microtiter plate reader (Thermo Electron, Marietta, Ohio, USA)
at 450 nm. To determine the repeatability, each serum sample
was measured in triplicate on the microtiter plate to calculate
intra-microtiter plate variation (mean CV%). Four samples were
measured on diﬀerent ELISA plates to calculate inter-microtiter
plate variation. Both LOD and LOQ were determined by a linear
regression analysis in analogy to the SRM and PRM measure-
ments. HSP90α levels obtained in SRM and PRM mode were
compared to ELISA measurements by correlation plots. Bland–
Altman plots for the ELISA to SRM/PRM method comparison
were constructed showing 95% limits of agreement. Methods
were considered to be in agreement if the chosen mean bias in-
terval was within ± 5%. The signiﬁcance of these method com-
parisons was determined by the Welch t-test.
2.7. Comparability of SIL Peptides and Immunoassay Standard
To determine the comparability of the SRM and PRM based on
the SIL peptides and the immunoassay recombinant HSP90α
standard (1 μg mL–1; calibration standard provided with the
ELISA kit), an amount of 4 ng of the HSP90 SIL peptides was
mixed with 2 ng of the immunoassay standard and reduced
(5.1 mM DTT), alkylated (15.1 mM IA), and trypsin (50 ng) di-
gested at 37 °C overnight. The sample which corresponded to
56.7 pg on column (3 μL of injection volume) was measured in
triplicate by SRMand PRMas described before. Subsequently the
ratios between the endogenous peptides of the HSP90α standard
and SIL peptides were used to determine the HSP90α concen-
tration. Additionally, to assess the purity of the protein standard
a data dependent acquisition was used. For nano-LC separation
(also 3 μL of corresponding sample), a linear gradient from 4
to 38% solvent B in 90 min was used and followed by a shot-
gun method with Orbitrap MS1 acquisition from m/z 400–1600
at 120 000 resolution (AGC = 40 000 ions) followed by ion trap
CID MS/MS spectra (30% normalized collision energy, AGC =
10 000 ions, and maximum injection time of 40 ms) for at most 3
s (‘top-speed’ type data-dependent acquisition method). Peptides
were identiﬁed and assigned to proteins by exporting features,
for whichMS/MS spectra were recorded, using the ProteoWizard
software (version 3.0.9248; http://proteowizard.sourceforge.net).
Resulting .mgf ﬁle was submitted to Mascot (version 2.3.02, Ma-
trix Science, London, UK) and applied to the human database
(UniProtKB/Swiss-Prot, version 151112, 20194 entries) for pro-
tein identiﬁcations. The following parameters were used: frag-
ment ion mass tolerance of 0.50 Da, parent ion mass tolerance
of 10 ppm, and maximum number of missed cleavages of two.
In the Mascot search engine oxidation of methionine was spec-
iﬁed as a variable modiﬁcation while carbamidomethylation of
cysteine was set as a ﬁxed modiﬁcation. Scaﬀold software (ver-
sion 4.7.5, Proteome Software Inc., Portland, OR) was used to
compute protein grouping, peptide probabilities, and protein
probabilities.[34] Peptides identiﬁed with Mascot ions sore >25
were considered to be true identiﬁcations. The MS proteomics
data have been deposited to the ProteomeXchange Consortium
via the PRIDE[26] partner repository with the dataset identiﬁer
PXD006615 https://doi.org/10.6019/PXD006615.
2.8. LOD/LOQ Comparison of PRM with ELISA
LOD/LOQ obtained by HSP90α ELISA were compared with
PRM only (not measured by SRM due to too low sensitivity).
For this purpose, serial dilutions of SIL peptides were prepared
in the pooled fraction of the SCX-fractionated QC1 sample (as
described above in the section: “ELISA-based quantiﬁcation”)
containing comparable concentrations of the HSP90α calibrants
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used for ELISA. The LOD and LOQwere calculated using regres-
sion analysis as described above in the section: “Data analysis”.
3. Results
We combined fractionation of peptides by SCX chromatography
of trypsin-digested serum with LC–MS in the SRM or the PRM
mode to quantify HSP90α and compared the results with a com-
mercially available HSP90α ELISA.
3.1. Linearity, LOD, and LOQ of SRM, PRM, and ELISA by Linear
Regression Analysis
An overview of the calculated LODs and LOQs for both SRM
and PRM assays (concentration range 0–30 ng mL–1), and for
the ELISA, for which a linear regression analysis was performed
as recommended by manufacturer (concentration range 0–4 ng
mL–1), is shown in Table 2. In addition, from an independently
prepared serial dilution (comparable to the ELISA range from
0–4 ng mL–1, according to the manufacturer) measured by PRM,
an R2 of 0.986 and 0.989 was obtained for YIDQEELNK be-
tween ELISA and DQVANSAFVER between ELISA, respectively.
In the PRM measurements and from regression analysis, the
LOD for both YIDQEELNK and DQVANSAFVER was found to
be 0.5 ng mL–1. An LOQ of 1.6 and 1.5 ng mL–1 was calculated
for YIDQEELNK and DQVANSAFVER, respectively. These val-
ues are signiﬁcantly lower than those listed in Table 2 and are
on a par with those obtained by ELISA. It can be seen from Ta-
ble 2 that in the SRM mode the LOD and LOQ values for both
peptides are considerably larger (by a factor of about 6) than in
the PRM mode, attesting to the superiority of the PRM method.
Table 2. Calculated LOD and LOQ levels in ng mL–1 for HSP90α in the
pooled fraction of the SCX-fractionated QC1 sample based on SIL pep-
tides YIDQEELNK and DQVANSAFVER for SRM, PRM, and for compara-
ble HSP90α ELISA measurements.
SRM




Peptide LOD (ng mL–1) LOQ (ng mL–1)
YIDQEELNK 1.0 (0.5)a 2.9 (1.6)a
DQVANSAFVER 1.3 (0.5)a 3.8 (1.5)a
ELISA
Cat No. ADI-EKS-895, Enzo Life Science LOD (ng mL–1) LOQ (ng mL–1)
HSP90α speciﬁc mouse monoclonal antibody 0.4 1.2
aCalculated if the same standard dilutions were used as described by the manufac-
turer of the ELISA.
Calibration curves for the two HSP90α SIL peptides spiked into
the pooled fraction of the SCX-fractionated QC1 sample as well
as for pure standards based on ﬁve serial dilutions (i.e. 0, 0.3,
1.2, 3.0, 6.0, and 30.0 ng mL–1) are shown in Supporting Infor-
mation Figure S1. High correlations between results of matrix-
spiked and pure conditions were obtained in PRM (>0.990). To
determine eﬀects due to matrix, the mean ratios were calculated
between the peak areas for the matrix-spiked and pure condi-
tions of all calibrants (0.3–30 ng mL–1) based on the calibra-
tion curves as seen in Supporting Information Figure S1. SRM
gave mean ratios of 252.3 and 295.9% for YIDQEELNK and DQ-
VANSAFVER, respectively. Similar ratios were obtained for PRM
for YIDQEELNK and DQVANSAFVER with 217.3 and 241.4%,
respectively. Thus, peptides spiked into matrix consistently gave
a stronger response compared to the pure peptide dissolved in
0.1% aqueous FA especially at low ng mL–1 concentrations. This
may be due to low adsorption as a result of other (sacriﬁcial) ma-
trix peptides which bind to the surface of the vial, as also observed
for oligonucleotides.[35] Linearity was better for peptides spiked
into matrix compared to those spiked into 0.1% aqueous FA for
SRM and PRM measurements.
3.2. Comparison of the Repeatability and Stability of SRM, PRM,
and ELISA Assay
The repeatability of PRM was signiﬁcantly better than for SRM
for both peptides YIDQEELNK (CV of 1.1% for PRM versus 8.4%
for SRM) and DQVANSAFVER (CV of 1.8% for PRM versus
11.8% for SRM, see Supporting Information Table S2). Repeata-
bility for PRM was also superior compared to the commercial
ELISA assay (intra-microtiter plate CV of 4.2%; inter-microtiter
plate mean CV of 7.5%, see Supporting Information Table S2).
The stability experiments showed CVs of 15.6% for
YIDQEELNK and 17.7% for DQVANSAFVER from repeated
measurements by SRM and 4.5 and 8.9% for PRM, respectively.
3.3. Quantiﬁcation of HSP90α by SRM, PRM, and ELISA
in Serum
Supporting Information Table S1 shows serum HSP90α levels
measured based on the proteotypic peptides YIDQEELNK relat-
ing to the α and β isoforms and DQVANSAFVER relating to the
α isoform, by SRM and PRM in comparison to ELISA. Both SRM
and PRM assays had adequate sensitivity to quantify HSP90α in
all trypsin-digested, SCX-fractionated serum samples. The mean
concentration of HSP90α across all sera measured by SRM was
73.4 ± 32.8 ng mL–1 based on the YIDQEELNK peptide, while
the DQVANSAFVER peptide gave a signiﬁcantly (unpaired t-test,
p = 0.001) higher concentration of 108.4 ± 60.7 ng mL–1, due to
a higher variance (see Figure 2A; more examples are shown in
Supporting Information Figure S2 in Supporting Information).
The mean concentration of HSP90α in the same set of samples
based on PRM measurements of the peptides YIDQEELNK and
DQVANSAFVER was 118.8 ± 66.7 ng mL–1 and 128.1 ng mL–1
± 72.7 ng mL–1, respectively, and these concentrations were not
diﬀerent (unpaired t-test, p = 0.539). Possible interference of
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Figure 2. SRM, PRM, and IT-PRM chromatograms of an identical SCX-fractionated serum sample (sample no. 28, see Supporting Information Table
S1) as observed in Skyline. An example of co-eluting peaks by means of misaligned transitions (y7, y8, and y9) for DQVANSAFVER was observed in
SRM (A) and IT-PRM (C). For comparison, the identical sample was measured by PRM simultaneously with SRM and IT-PRM measurements (B and D,
respectively). More examples of these probable interfering co-eluting peaks are shown in Supporting Information Figure S2 and S7.
Proteomics Clin. Appl. 2018, 12, 1700107 C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1700107 (7 of 12)
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Figure 3. Representation of the variability in the transitions of the HSP90α proteotypic peptide DQVANSAFVER measured by SRM (A) and PRM (B).
Bars represent normalized peak areas (% of total) of the transitions y7 (red), y8 (black), and y9 (blue) in 43 SCX-fractionated serum samples from
healthy subjects. Sample number 44 corresponds to 1 fmol of the pure (0.1% aqueous FA) SIL peptide. See Supporting Information Figure S3 for the
corresponding results for YIDQEELNK.
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co-eluting compounds was not observed in PRM due to the
higher mass resolution (see Figure 2B or 1D and Support-
ing Information Figure S2). The CVs for the most intensive
DQVANSAFVER-related transition y8 were 15.0% and 5.8% in
SRM and 2.5% and 1.2% in PRM for the endogenous and the
SIL peptides, respectively (Table 1; Figure 3). Comparison of the
weighted CVs for the y-ions of YIDQEELNK with y-ions of DQ-
VANSAFVER showed that these CVs were signiﬁcantly diﬀerent
for SRM but not for PRM indicating interference in the SRM
assay. For both SRM and PRM the SIL peptides showed better
weighted CVs compared to the endogenous peptides, but the
concentration of the SIL peptides was higher (on average ﬁve
times).
The correlation between HSP90α concentrations based on
SRM measurements of YIDQEELNK and DQVANSAFVER was
poor with an R2 of 0.642 (Supporting Information Figure S4A;
Supporting Information Table S3) and signiﬁcantly worse com-
pared to PRM (R2 = 0.894). Correlations above 0.7 were con-
sidered as good.[36] To compare the SRM and PRM measure-
ments with an established assay, the same serum samples were
measured with a commercially available HSP90α ELISA as illus-
trated in Supporting Information Figure S5, giving an average
concentration of 113.7 ± 60.1 ng mL–1. This was in excellent
agreement (unpaired t-test, p = 0.465) with the PRM measure-
ments for both peptides (average 123.9 ± 69.6 ng mL–1). Com-
parison of PRM with ELISA showed an R2 of 0.878 and 0.811 for
YIDQEELNK and DQVANSAFVER, respectively (Supporting In-
formation Figure S4E and F; Supporting Information Table S3).
Correlation was not signiﬁcantly diﬀerent for YIDQEELNK
(p = 0.709) and DQVANSAFVER (p = 0.295) as determined by
the Welch t-test. Correlation of SRM and ELISA data reached R2
values of 0.764 and 0.652 for YIDQEELNK and DQVANSAFVER
peptides, respectively (Supporting Information Figure S4C and
D; Supporting Information Table S3). Measured concentrations
of HSP90α were signiﬁcantly diﬀerent for the SRM assay based
on YIDQEELNK (p < 0.001) and the ELISA results but not for
SRM based on DQVANSAFVER (p = 0.686) although signiﬁ-
cantly more variation was observed for DQVANSAFVER than for
YIDQEELNK (Table 1 and Figure 2 and Supporting Information
Figure S3). Comparison of the measured concentrations by SRM
and PRM with the ELISA in a Bland–Altman plot with a ± 95%
conﬁdence interval showed a bias of –41.0% for the YIDQEELNK
endogenous peptide measured in SRM (Supporting Information
Figure S6), while PRM had a bias of 3.9 %. The bias for DQ-
VANSAFVERwas –5.7 and 11.1%by SRMandPRM, respectively.
The kind and degree of interference of unknown components can
vary from sample to sample and this causes SRM signals to dis-
play a much larger spread than PRM signals because these un-
known components have less chance to be included in the PRM
experiments, see Figure 3.
3.4. Comparability of SIL Proteotypic Peptides with HSP90α
as Calibration Standard
Onemajor diﬀerence betweenMS-basedmethods and the ELISA
assay is that the ﬁrst uses stable isotope labeled, synthetic, and
proteotypic peptides as standards while the latter uses HSP90α
protein. In order to make a link between these two principles
of assay calibration, we mixed 4 ng of our SIL peptides with
2 ng of the ELISA standard as described in the section: “Ex-
perimental Section” and measured the HSP90α concentration
by SRM and PRM, respectively. In this way, the ﬁnal concen-
tration of the ELISA standard is 1.0 μg mL–1. SRM and PRM
measurements based on YIDQEELNK gave 1.4 and 1.1 μg mL–1
HSP90α, respectively. Both SRM and PRMmeasurements based
on DQVANSAFVER gave a signiﬁcantly lower concentration of
0.36 μg mL–1 HSP90α. To gain a better insight into this unex-
pected discrepancy, we evaluated the purity of theHSP90α ELISA
standard by shotgun proteomics using a data-dependent acqui-
sition approach. A database search resulted in 32 (Supporting
Information Table S4) identiﬁed proteins of which the top ﬁve
hits (based on number of exclusive unique peptide counts) were
related to high-abundant proteins (e.g. serum albumin, various
types of keratin I and II) while HSP90α was ranked halfway of
the list. The results showed further that identiﬁcation of HSP90α
was based on only 2% sequence coverage related to one peptide
that did not correspond to the two selected proteotypic peptides
used for this study. The protein complexity of the ELISA stan-
dard used in the ELISA could well explain the discrepancy ob-
served above between ELISA andMSbased techniques (SRMand
PRM). Thus, these results show that while the HSP90α ELISA
standard can be ideal for immunoassays, it is not very easy to
use in MS based analyses because the HSP90α ELISA standard
contains other proteins.
3.5. High-Resolution PRM and PRM at Quadrupole Mass
Resolution (IT-PRM)
To rule out the possibility that the discrepancy observed between
SRM and PRM is due to instrument eﬀects, we measured four
fractions of three diﬀerent SCX-fractionated serum digests (sam-
ple no. 9, 28, and 32; Supporting Information Table S1) by SRM,
IT-PRM (PRM at quadrupole ion trap resolution), and PRM
(high-resolution) (Figure 2 and Supporting Information Figure
S7). Co-eluting peaks seen in SRMwere also observed in IT-PRM;
while in PRM, no such observation was observed for identical
samples by applying the appropriate resolution settings during
data analysis. The variation of transitions related to endogenous
and the SIL peptides YIDQEELNK and DQVANSAFVER mea-
sured by IT-PRM and PRM at three points (apex, half-height,
and one-quarter-height) of the peak is illustrated in Supporting
Information Figure S8. For PRM, the intensities of each tran-
sition extracted from the three measured points of the endoge-
nous peptides showed little aberration (weighted CV of 3%
for both YIDQEELNK and DQVANSAFVER, Supporting Infor-
mation Table S5), while variation for IT-PRM was considerably
larger (highest weighted CV of 33.1% (y7-ion) for YIDQEELNK;
highest weighted CV of 9.9% (y9-ion) for DQVANSAFVER, Sup-
porting Information Table S5; see formore details Supporting In-
formation Figure S9). Transitions for pure SIL peptides showed
almost identical intensities at the three measurement points by
IT-PRM and PRM. These results show that the poorer perfor-
mance of SRM in comparison to PRM is due to the lower res-
olution of ion analysis rather than instrumental parameters.
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4. Discussion
We developed a quantitative 2D-LC–MS/MS assay using
SRM and PRM technology to measure HSP90α concentra-
tions relating to two proteotypic peptides YIDQEELNK and
DQVANSAFVER. The DQVANSAFVER is HSP90α speciﬁc,
while the peptide YIDQEELNK relates to both HSP90α and
β isoforms. However, it is very likely that only the α isoform was
measured due to presence of a very low contribution in serum
of the β isoform (1–2 ng mL–1) as known from literature.[27,28]
Both YIDQEELNK and DQVANSAFVER peptides could have
posttranslational modiﬁcations like phosphorylation considering
the presence of serine and tyrosine in their sequence. It is very
unlikely that these peptides are phosphorylated according to
literature (http://www.uniprot.org). However, some references
(http://www.phosphosite.org)[37–39] indicate that phosphory-
lation site of S505 can be phosphorylated in a few cell lines.
By phosphoproteomics of cervical tissue and serum from a
healthy volunteer, we could not detect such phosphorylation
using TiO2-based phosphopeptide enrichment for both peptides
YIDQEELNK and DQVANSAFVER. Therefore, we assume that
the contribution of phosphorylation is negligible.
To achieve suﬃcient sensitivity to detect HSP90α peptides,
trypsin-digested sera were fractionated by SCX chromatography.
Both HSP90 peptides were highly stable in SCX-fractionated
serum and thus very suitable for this comparison. Comparison of
the data of high-resolution MS in PRM mode compared to SRM
showed signiﬁcant better performance for PRM with respect to
linearity, repeatability, sensitivity, and the almost complete re-
moval in PRM of components which co-elute in SRM. This re-
sulted for PRM in a better LOD and LOQ compared to SRM and
an almost identical LOD/LOQ ratio compared to ELISA. PRM
results for both endogenous YIDQEELNK and DQVANSAFVER
gave comparable levels to ELISA measurements (p = 0.709 and
0.295, respectively) and correlated better for both peptides with
ELISA data (R2 = 0.878 and 0.811, respectively) than levels ob-
tained by SRM (R2 = 0.764 and 0.652, respectively; Supporting
Information Figure S4). SRM results based on YIDQEELNK dif-
fered signiﬁcantly (p < 0.001) from the results of a commer-
cial HSP90α ELISA, while those from the other peptide DQ-
VANSAFVER showed no signiﬁcant diﬀerence (p = 0.686). This
was unexpected because intense co-eluting peaks were observed
for DQVANSAFVER but not for YIDQEELNK in SRM mode.
From this, it can be concluded that co-eluting peaks do not cor-
relate linearly with the observed diﬀerences. PRM showed al-
most no detectable co-eluting peaks (Figure 3) as was observed in
SRM. Altogether PRM for YIDQEELNK- and DQVANSAFVER-
derived fragment ions compared to SRM fragment ions resulted
in much better weighted CVs as shown in Table 1. Signiﬁcantly,
more variation (weighted CV) was observed for endogenous DQ-
VANSAFVER than for YIDQEELNK when measured by SRM,
while PRM measurements did not show signiﬁcant diﬀerences.
The SIL peptides showed a similar eﬀect, but to a lesser extent be-
cause on average ﬁve times more SIL peptide was used than the
measured endogenous peptide. It is the variability of interfering
(unidentiﬁed) components which causes the SRM signals to dis-
play a much larger spread than PRM signals, as also exempliﬁed
in Figure 3.
PRM is a technique that monitors all product ions within a cer-
tain scan range meaning that fragment ion intensities are avail-
able for all observed fragments in PRM in contrast to SRM. For
this reason, beyond the preselected ions (y5, y6, y7, y8, and y9 for
both HSP90 peptides) more transitions can be evaluated. Select-
ing other transitions than used in this study did not aﬀect the re-
sults; for comparison reasons only the transitions used for SRM
were analyzed.
To rule out that discrepancies between SRM and PRM that
were caused by a variation in experimental conditions (for in-
stance chromatography), four SCX fractions were measured by
IT-PRM (to resemble a triple quadrupole instrument as close
as possible) and PRM on identical sample material in the same
device. It is expected that distribution of the transition inten-
sities should align to each other if no interfering of co-eluting
peaks (as demonstrated for the pure SIL peptides) were present.
The deviation of the ideal situation became larger for low inten-
sity mass transitions related to both endogenous peptides ob-
served by PRM measurements, while in IT-PRM mode signiﬁ-
cantly more deviation for all transitions (low and high intense)
was noted compared to the pure peptide. This emphasized that
SRM and IT-PRM are more susceptible to variation than PRM
due to the lowermass resolution of the fragment ion spectra. Dif-
ferences achieved by PRM were, therefore, not due to diﬀerent
sample handling, ion-generation, or chromatography, but due to
the application of high-resolution MS that reduced the number
of co-eluting peaks that potentially generate interference. By the
application of high-resolution MS, a much better selection of the
peptide of interest and its transitions can bemade than in a triple
quadrupole and possible interferences of neighboring co-eluting
peaks can be avoided resulting in better sensitivity and repeata-
bility. Overall, PRM resulted in better analytical performance for
the YIDQEELNK and DQVANSAFVER peptides (both endoge-
nous and SIL) compared to SRM.
The accurate determination of the amount of molecules is dif-
ferent for immunoassay and PRM. In immunoassay, mostly a
recombinant protein is used that can be accurately measured
by a protein assay. In these determinations, it is assumed that
a recombinant protein mimics the protein present in a tis-
sue or a bioﬂuid. In SRM and PRM, SIL peptides are synthe-
sized, puriﬁed, and an accurate composition of amino acids
is determined assuming resemblance with the peptide, which
is part of the protein of interest. Therefore, variations in the
correct concentration of standards can be expected in these
techniques. Bland–Altman plots (Supporting Information Fig-
ure S6) were calculated to determine whether the SRM and
PRM were in agreement with ELISA results. From this, it was
concluded that the YIDQEELNK peptide measured by PRM
(and no peptides for SRM) was similar to ELISA measure-
ments based on chosen criteria (within ± 5% bias interval level).
For the peptide DQVANSAFVER measured by PRM, it was
not expected that it would fall outside the criteria of 5% (i.e.
11.1%), since it reached in general good results in all condi-
tions as described before in terms of repeatability, low LOD/LOQ,
no co-eluting peaks, and good correlation with ELISA. How-
ever, as was discussed above (see Table 1), the peptide DQ-
VANSAFVER was found to generally perform slightly less than
YIDQEELNK.
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Comparability experiments in which the HSP90α level of the
ELISA standard was determined by SRM and PRM measure-
ments revealed that the discrepancy might be explained by the
presence of many other proteins than HSP90α in this HSP90α
standard. Likely, the presence of these extra proteins could in-
ﬂuence the SRM and PRM measurements if no fractionation is
performed.
We demonstrated the high reproducible, robustness, and sen-
sitive PRM assay to determine HSP90α concentrations in SCX-
fractionated sera at relative low ng mL–1 level. The sensitivity by
PRMwas in agreement as determined by ELISA data and showed
better repeatability. By PRM and SRM, the quality of samples can
easily be assessed by an aberrant transition distribution (Figure
3), whereas by ELISA results caused by aberrations in the assay
are much more diﬃcult to detect.
If fractionation of biological samples is technically feasible,
PRM can be used as an attractive alternative for immunoassay
to quantify highly reproducible proteins at the ng mL–1 scale in
complex protein mixtures including sera without the use of anti-
bodies or comparable binders.
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